ASX AND MEDIA RELEASE

Race signs agreement with Crystal Pharmatech

25 July 2016, Perth, Australia: Race Oncology Ltd (ASX: RAC) today announced that it had signed a development agreement with Crystal Pharmatech, Inc., a New Jersey-based contract research organization. The agreement covers a development program over a period of up to three months.

Pharmaceutical manufacturing and formulation techniques have improved greatly since the 1990s, when Bisantrene development was stopped. The program with Crystal Pharmatech is aimed at developing improved salt forms of Bisantrene, purification of the drug, and a process for developing an optimum formulation, using contemporary manufacturing and formulation technology.

"This project is one of first development steps in our progress towards a filed IND (Investigational New Drug application)," said Managing Director, Peter Molloy. "We expect it will result in an optimised Bisantrene drug product and formulation that will become the basis for our submission to the FDA and the final manufactured Bisantrene product that we bring to market in Europe under our Named Patient Program."

Once the product optimisation project is completed, the Company intends to transfer the process to a third party GMP manufacturer for production to meet clinical requirements and expected sales demand under the NPP in Europe.

About Race Oncology

Race Oncology is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company's first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrene and has secured Orphan Drug Designation in the US. The Company's goal is to complete final development of Bisantrene and bring this valuable cancer drug to market.

For more information, contact: **Peter Molloy**
Managing Director
T: +61 (0) 3 9097 1656
M: +61 (0) 418 174 816